Federal grants to Altis Biosystems, Inc.
Altis Biosystems, Inc. in Research Triangle Park, North Carolina received $8.4 million in federal grants from fiscal 2021 to 2025, across 9 awards. Its largest program was National Center for Advancing Translational Sciences, with $4.4 million. In fiscal 2025 it was awarded $835,939.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$8.4 million
- Awards9
- Awarded in FY 2025$835,939
- Largest award$2.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 2 | $955,884 |
| FY 2022 | 4 | $2.5 million |
| FY 2023 | 4 | $3.1 million |
| FY 2024 | 1 | $913,659 |
| FY 2025 | 1 | $835,939 |
Programs that fund Altis Biosystems, Inc.
| Program | Awards | Amount |
|---|---|---|
| National Center for Advancing Translational Sciences | 4 | $4.4 million |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 5 | $4.0 million |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 9 | $8.4 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Inflammagut: a drug-screenable co-culture system using gut-associated lymphocytes and autologous primary human gut epithelium that reports inflammation - project summary a broad range of inflammatory gastrointestinal conditions impact millions of people in the united states and abroad. The etiology | National Center for Advancing Translational Sciences | April 30, 2022 | $2.0 million |
| A 2D intestinal crypt platform for compound screens - project summary intestinal epithelium is the fastest dividing tissue in the body, and the health of the cells can be easily impacted by environmental toxins and drugs. This organ system is therefore a prime target for biological testing of medici | Diabetes, Digestive, and Kidney Diseases Extramural Research | September 22, 2022 | $1.9 million |
| Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk - project summary gi side effects, such as ulcers and diarrhea, represent the most common source of adverse events for pharmaceuticals. Gi stem cells are responsible for repairing and replenishing gi e | National Center for Advancing Translational Sciences | June 27, 2023 | $1.8 million |
| Mucus and ali models of the human intestine - project summary the mucus layer is the first line of defense against infiltration of microorganisms, digestive enzymes and acids, digested food particles, microbial by-products, and food-associated toxins. This layer coats the interior surface of the gi | Diabetes, Digestive, and Kidney Diseases Extramural Research | June 9, 2025 | $835,939 |
| Developing an optimized cell based platform for assays of the gastrointestinal enteroendocrine system | Diabetes, Digestive, and Kidney Diseases Extramural Research | June 28, 2021 | $699,341 |
| Metabolgut: a rapid assay platform to evaluate the impact drugs on lipid-handlingpathways and chylomicron-associated drug distribution using stem cell-drivenhuman absorptive enterocytes. - project summary maintaining healthy physiology of the human gut is a large focus of pharma. Models to study dru | National Center for Advancing Translational Sciences | August 14, 2023 | $343,297 |
| A mucus-producing intestinal epithelium model for in vitro drug absorption testing - project summary the mucus layer is the first line of defense against infiltration of microorganisms, digestive enzymes and acids, digested food particles, microbial by-products, and food-associated toxins. This laye | Diabetes, Digestive, and Kidney Diseases Extramural Research | May 6, 2022 | $293,991 |
| Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk - project summary gi side effects, such as ulcers and diarrhea, represent the most common source of adverse events for pharmaceuticals. Gi stem cells are responsible for repairing and replenishing gi e | National Center for Advancing Translational Sciences | June 23, 2022 | $256,574 |
| A 2D intestinal crypt platform for compound screens - project summary intestinal epithelium is the fastest dividing tissue in the body, and the health of the cells can be easily impacted by environmental toxins and drugs. This organ system is therefore a prime target for biological testing of medici | Diabetes, Digestive, and Kidney Diseases Extramural Research | June 30, 2021 | $256,543 |
Questions people ask
How much federal grant money does Altis Biosystems, Inc. get?
$8.4 million in 9 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Altis Biosystems, Inc. the most?
The Department of Health and Human Services, with $8.4 million in 9 awards.
What is Altis Biosystems, Inc.'s largest federal grant?
$2.0 million under National Center for Advancing Translational Sciences, with its first action in the period on April 30, 2022. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Altis Biosystems, Inc.?
Its largest are National Center for Advancing Translational Sciences and Diabetes, Digestive, and Kidney Diseases Extramural Research.
Other grant recipients in Research Triangle Park
- Research Triangle Institute
- Epicypher, Inc.
- T3D Therapeutics, Inc.
- Redbud Labs, Inc.
- Dignify Therapeutics, LLC
- Zymtronix Catalytic Systems, Inc.
- 21MEDTECH LLC
- North Carolina Biotechnology Center
Largest federal grant recipients in North Carolina · Federal grants in North Carolina